Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

Dapavo, Paolo; Siliquini, Niccolò; Mastorino, Luca; Avallone, Gianluca; Merli, Martina; Agostini, Andrea; Cariti, Caterina; Viola, Riccardo; Stroppiana, Elena; Verrone, A; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone

doi:10.1080/09546634.2021.1961998

Cited by 41 publications

(67 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysing the treatment outcomes of the whole cohort with regard to previous biologic exposure revealed higher rates of PASI 50, PASI 75, PASI 90 and PASI 100 responses in biologic-naïve patients as compared to in biologic-non-naïve patients at 3, 6 and 12 months after treatment initiation (Table S2 ). These findings are consistent with results from clinical trials and first real-world data, which show a better treatment outcome in biologic-naïve patients or patients directly randomized to the IL-23p19 arm instead of the biologic crossover arm 9 , 23 , 26 , 30 , 32 , 36 , 37 . However, it appears as though the class of the previously administered biologic does not influence the effectiveness of the IL-23p19 inhibitors (Table 4 ).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

Graier

Weger

Jonak

et al. 2022

Sci Rep

View full text Add to dashboard Cite

With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19, three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis. However, poorer skin improvement as well as higher rates of serious adverse events have been reported for patients under real-world conditions (outside clinical trials). This accounts especially for patients who have already been treated with biologic drugs. We therefore aimed to determine effectiveness and safety of IL-23p19 inhibitors in real-world patients by analysing data from the Psoriasis Registry Austria (PsoRA) in this observational, retrospective, multicentre cohort study. Data for 197 patients (52.3% biologic-non-naïve), who were treated with anti-IL-23p19 antibodies (127 guselkumab, 55 risankizumab and 15 tildrakizumab) for at least 3 months, were eligible for analysis. In general, biologic-non-naïve patients displayed a less favourable response to anti-IL-23 treatment as compared to biologic-naïve patients. However, after correction for previous biologic exposure, few differences in PASI improvement were detected among biologic-naïve and -non-naïve patients treated with different IL-23p19 inhibitors. This indicates that treatment effectiveness is not related to the class of the previously administered therapy in biologic-non-naïve patients. Therefore, IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics. However, as with other biologic agents (including IL-17 inhibitors), we did not observe an entirely satisfactory treatment response (i.e. PASI < 3 and/or PASI 75) to anti-IL-23 treatment in one out of four to five patients. Adverse events (mainly non-severe infections) were observed in 23 (11.7%) patients with no major differences regarding the administered IL-23 inhibitor or previous biologic exposure.

show abstract

Section: Discussionsupporting

confidence: 90%

“…2 , Table 5 ) 20 – 22 . In general, these response rates are also in the range (or slightly lower) as those recently published from Italian real-world patient cohorts 23 – 25 .…”

Section: Discussionsupporting

confidence: 56%

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

Graier

Weger

Jonak

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The latter finding is notable, as in previous literature higher discontinuation rates due to ineffectiveness have been described for other types of biologics (4). Previous studies on guselkumab DS in realworld settings have also reported high firstyear DS (ranging from 68.0% (5) to 95.0% ( 6)), although sample size was often small, and the event definition and duration of followup varied (5)(6)(7)(8)(9)(10)(11).…”

Section: Discussionsupporting

confidence: 56%

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis

Muijen

Thomas²,

Vellinga³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…Risankizumab is the latest biologic treatment approved by Food and Drug Administration and European Medical Agency for moderate-tosevere plaque psoriasis. 1,2 This new biologic, a humanized IgG1 monoclonal antibody, targets the p19 subunit of IL-23. 3 High levels of efficacy and safety have been demonstrated in different clinical trials (UltIMMA-1 and -2, IMMerge, IMMvent, SustaIMM).…”

Section: Introductionmentioning

confidence: 99%

“…Risankizumab is the latest biologic treatment approved by Food and Drug Administration and European Medical Agency for moderate‐to‐severe plaque psoriasis. 1 , 2 This new biologic, a humanized IgG1 monoclonal antibody, targets the p19 subunit of IL‐23. 3 …”

Section: Introductionmentioning

confidence: 99%

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Mastorino

Susca

Megna

et al. 2022

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience. Our objectives were to evaluate the effectiveness and safety of Risankizumab and to investigate on possible predictor factors response. We retrospectively analyzed 166 patients from two centers in Italy who undergone Risankizumab for psoriasis. The proportion of patients achieving a 100%, 90%, 75% of improvement in Psoriasis Area Severity Index (PASI) and PASI <3 were collected at weeks 16, 28, 40, and 52. Study population was analyzed in subgroups to investigate possible predictors of response to Risankizumab since week 40. At the time of analysis 165, 103, 30, and 11 patients had completed 16, 28, 40, and 52 weeks of treatment, respectively. The mean PASI score decreased from 12.5 ± 5.1 at baseline to 1.9 ± 2.4 at week 16. Similar reductions were observed when considering PASI <3, PASI 75, PASI 90, and PASI 100. Previous biologics failure, different smoking habits, obesity, and joint involvement resulted in a lower response to risankizumab. In particular, significant differences in mean PASI at any time‐points was observed between psoriatic arthritis (PSA) and non‐PSA patients: 2.7 versus 1.7 (p = 0.036), 1.9 versus 0.4 (p = 0.006), and 4.1 versus 0.5 (p = 0.016) at 16, 28, and 40 weeks, respectively. No difference in response to risankizumab occurred in the case of involvement of difficult‐to‐treat areas. In this population, Risankizumab was effective and safe. Smoking habits, joint involvement, obese status, and previous biologic experience may negatively affect treatment response, while difficult body sites involvement have minor impact.

show abstract

Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

Cited by 41 publications

References 15 publications

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Contact Info

Product

Resources

About